Rogers James William sold $634K of TEM

Rogers James William (Chief Financial Officer) sold 11,529 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.63M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Jun 30, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO for ~$634k, executed under a pre-arranged 10b5-1 plan; this is generally treated as routine unless paired with other negative fundamentals.

02

Market read

Traders may monitor for insider selling trends, but this specific disclosure is unlikely to drive a major repricing on its own.

03

What to watch

The filing does not disclose reasons for the sale beyond the existence of a 10b5-1 plan; without additional context (e.g., other insiders buying, earnings timing), the signal is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed late June 29; sale dated June 25.

Background

The article summarizes an SEC Form 4 insider transaction for Tempus AI, Inc. (TEM) involving the CFO.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CFO Rogers James William sold 11,529 shares in an open-market transaction for about $634,095 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive negative information.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of valuation or liquidity needs; traders may still fade rallies if selling cadence continues.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; ticker TEM.

  • Rogers James William

    Chief Financial Officer who sold 11,529 shares.

  • 10b5-1 plan

    Pre-arranged trading plan that reduces the informational content of the sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.